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Safety of catheter-directed thrombolysis for deep
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Background: The current study was conducted to demonstrate that catheter-directed thrombolysis for upper and lower
extremity deep vein thrombosis is equally safe in patients with and without cancer.
Methods: A retrospective cohort of consecutive patients with acute iliofemoral or brachiosubclavian deep vein thrombosis
treated with catheter-directed thrombolysis was identified. Demographic characteristics and clinical outcomes were
compared between patients with cancer and without cancer.
Results: Catheter-directed thrombolysis was used to treat 202 limbs in 178 patients (75 limbs in 61 cancer patients and
127 limbs in 117 patients without cancer). The mean treatment duration for patients with cancer (29.7  21.2 hours)
and without cancer (28.8  22.2 hours) was similar (P  .7774). Catheter-directed thrombolysis achieved grade III clot
lysis in a similar proportion of cancer patients (50 of 75 limbs, 66.7%) and patients without cancer (82 of 127 limbs,
64.6%; P  .7619). Grade II clot lysis also was achieved in equal numbers of patients with (20 of 75 limbs, 26.7%) and
without cancer (34 of 127 limbs, 26.8%; P  .9872). Three cancer patients (4.9%) and four noncancer patients (3.4%)
experienced major bleeding during catheter-directed thrombolysis (P  .6924). Pulmonary embolism occurred in 1.6%
(1 of 61) of cancer patients and in 1.7% (2 of 117) of patients without cancer (P  .9999) during catheter-directed
thrombolysis. Patients aged >70 years had an increased risk of major bleeding.
Conclusion: Percutaneous catheter-directed thrombolysis is equally safe for patients with and without cancer who have
acute symptomatic deep vein thrombosis. ( J Vasc Surg 2008;47:388-94.)More than 350,000 Americans are diagnosed with a
deep vein thrombosis (DVT) each year.1 Symptomatic
DVT is particularly common among cancer patients, occur-
ring in as many as 15% during the clinical course of their
disease.2 Compared with patients without cancer, cancer
patients who have DVT are at increased risk for recurrent
venous thromboembolism (VTE) and anticoagulation-
associated bleeding. In addition, cancer patients with
VTE have a twofold higher mortality rate than cancer
patients without thrombotic events.2-4
Standard medical therapy with anticoagulation is very
effective at preventing thrombus progression and pulmo-
nary thromboembolism.5 However, anticoagulation does
not directly promote thrombus dissolution,6 and as conse-
quence, many patients have residual thrombus at the end of
treatment that predisposes them to the development of
venous valvular dysfunction and post-thrombotic syn-
drome.7,8 This consideration is particularly relevant for
cancer patients, who often have greater initial clot burdens
in proximal veins and achieve less venographic improve-
ment on anticoagulation than patients without cancer who
develop DVT.2
From the Russell H. Morgan Department of Radiology and Radiological
Science,a and the Departments of Surgery,b Biostatistics,c and Medicine,d
Johns Hopkins University School of Medicine.
Competition of interest: none.
Reprint requests: Hyun S. Kim, MD, 600 NWolfe St, Blalock 545, Division
of Vascular and Interventional Radiology, Russell H. Morgan Depart-
ment of Radiology and Radiological Science, Johns Hopkins University
School of Medicine, Baltimore, MD 21287-4010 (e-mail: sikhkim@
jhmi.edu).
0741-5214/$34.00
Copyright © 2008 by The Society for Vascular Surgery.
doi:10.1016/j.jvs.2007.10.033
388In contrast to conventional anticoagulation, catheter-
directed thrombolytic (CDT) therapy can result in a rapid
reduction in thrombus burden, symptom relief, preserve
venous valvular function, and potentially reduce the risk of
recurrent thrombosis.9 In a large multicenter study, CDT
was associated with complete or partial clot lysis in 83% of
patients and a significantly improved quality of life com-
pared with a historical cohort of patients treated with
anticoagulation alone.10,11
Despite its potential benefits, CDT is also associated
with greater potential risks than conventional anticoagula-
tion, including a greater risk of major bleeding, longer
hospital stays, and higher medical costs.12,13 These disad-
vantages and the greater risk of bleeding complications in
patients with cancer have limited the acceptance of endo-
vascular DVT therapy in oncology patients.13-15 As a con-
sequence, patients with malignancies have been excluded
from participation in a number of clinical trials of throm-
bolysis for DVT.16-18 However, to our knowledge, no
direct comparisons of CDT in patients with cancer and
without cancer have been reported to date to confirm this
clinical impression of heightened risks of CDT in patients
with malignancies. The present study was conducted is to
test our hypothesis that CDT is an equally safe treatment
for patients with and without cancer who have acute prox-
imal extremity DVT.
MATERIALS AND METHODS
Patients. After Institutional Review Board approval
was obtained, we searched our clinical database to retro-
spectively identify patients who were treated percutane-
ously for symptomatic extremity DVT. The study was
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tion 14 days) proximal iliofemoral or brachiosubclavian
DVT who underwent CDT with urokinase (Abbott Labo-
ratories, North Chicago, Ill), alteplase (Genentech, South
San Francisco, Calif), or reteplase (Centocor, Malvern, Pa)
betweenMay 1995 and January 2007. Patients treated with
CDT were divided into two groups for analysis; one group
had active cancer and patients in the other group were
without a known malignancy.
Active cancer was defined as the presence of a patho-
logic diagnosis of cancer (excluding basal cell or squamous
cell cancer of the skin) for which the patient was undergo-
ing treatment with chemotherapy, radiotherapy, or surgery
at the time of the thrombotic event. Patients with measur-
able recurrent or metastatic cancer not undergoing active
treatment at the time of their DVT diagnosis or6months
of diagnosis were also considered to have active cancer.
The following information was collected on each sub-
ject by chart review: demographic data, clinical data rele-
vant to the subject’s thrombotic event, immediate clinical
efficacy, including the degree of thrombus reduction; the
treatment duration, the total lytic dose, and the periproce-
dural complications of therapy.
Thrombolytic technique. All patients were treated
initially with a continuous intravenous infusion of unfrac-
tionated heparin, adjusted to maintain an activated partial
thromboplastin time (aPTT) ratio between 2 and 2.5 times
control. Before the initiation of CDT, informed consent
was obtained from each patient after a discussion of the
risks of bleeding complications and benefits of nonsurgical
treatment of DVT with CDT and thrombectomy. The
presence of contraindications to percutaneous thromboly-
sis, including primary or metastatic central nervous system
malignancy, coagulopathy, stroke 3 months, surgery 1
month, or gastrointestinal bleeding 3 months was as-
sessed. Patients at risk for cerebrovascular accidents or
cerebral metastasis were further evaluated by computed
tomography before CDT treatments.
Percutaneous access to the thrombosed vessel was
achieved through the popliteal vein for lower extremity
DVT or the brachial vein for upper extremity DVT. Using
a 6F vascular sheath (Cordis, Miami, Fla), we crossed the
clots using a 5F hydrophilic hockey-stick catheter (Terumo
Medical, Somerset, NJ) and a 0.035-in hydrophilic guide
wire (Terumo Medical) combination. Venograms were
performed using iodine contrast through the sheath or
catheter. In patients with impaired renal function (serum
creatinine level 1.5 mg/dL or creatinine clearance 60
ml/min), gadolinium or carbon dioxide gas contrast was
used.
In patients who received adjuvant percutaneous me-
chanical thrombectomy (PMT), we performed PMT using
a 6F over-the-wire Angiojet rheolytic thrombectomy cath-
eter (Possis Medical, Minneapolis, Minn) or an 8F Trellis-8
peripheral infusion system (Bracchus Vascular Inc, Santa
Clara, Calif). We performed PMT in a peripheral to central
direction in two to three cycles. Residual thromboses were
treated with CDT. Patients who were treated with PMTalone, without CDT, or who were treated with the Power-
Pulse spray technique with the AngioJet device were ex-
cluded from the study.
All CDT procedures were initiated through multi-
side-hole infusion catheters (Angiodynamics, Queens-
bury, NY) that were securely placed within the thrombosed
veins. Catheter-directed thrombolysis was performed using
urokinase, alteplase, or reteplase. The individual attending
physicians performing the procedures determined the dura-
tion and rate of infusion. No predetermined time points were
set for either venographic assessments or the termination of
therapy. Use of PMT was left to the discretion of the
individual attending physicians and according to the oper-
ator’s prior experience.
Any stenosis remaining after thrombolysis was treated
with balloon venoplasty using balloon angioplasty catheters
or stents. During CDT, subtherapeutic doses (250-500
U/h) of unfractionated heparin were given through the
access sheath to maintain patency.
At the completion of CDT, intravenous unfractionated
heparin was reinitiated to maintain an aPTT ratio of 2 to
2.5 times control, followed by ongoing oral anticoagula-
tion with warfarin adjusted to maintain an international
normalized ratio of 2 to 3. The duration of warfarin
therapy was determined by the patients’ referring attend-
ing physicians.
The general practice of physicians at The Johns Hop-
kins Hospital is to treat patients with a DVT with warfarin
therapy for at least 3 months. Longer durations of therapy
are considered for patients with idiopathic thrombotic
events or in the presence of thrombophilic conditions
associated with a significant risk of recurrent thromboem-
bolism. Cancer patients with VTE are generally treated for
the duration of their active cancer and its treatment or for a
period appropriate for their thrombotic event (at least 3-6
months), whichever was longer. Low-molecular-weight
heparin was not routinely used for the long-term treatment
of VTE in cancer patients in this cohort.
Study end points and definitions. The study end
points were the rate of clot lysis, major bleeding, and
pulmonary embolism during CDT of proximal extremity
DVT in patients with and without cancer. Clot lysis was
assessed quantitatively by comparison of venograms per-
formedbefore and after treatment. Post-treatment venograms
were performed at the end of thrombolysis but before any
adjunctive procedures such as balloon venoplasty or stent
placement.
The percentage of clot lysis was estimated by the
difference between the volume of thrombus before and
after treatment. Clot lysis was categorized as grade III if
complete clot lysis occurred, grade II if 50% to 99% clot
lysis occurred, and grade I if 50% clot lysis was
achieved.11,19 Treatment duration and lytic doses were
retrieved from the medical record. Efficacy was analyzed
on a per-limb basis.
Major bleeding was defined as any clinically overt
bleeding that resulted in the cessation of therapy, further
hospitalization, permanent sequelae, or death; or a decrease
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transfusion of 2 U of blood, or surgical intervention. All
other bleeding episodes were considered minor.19,20
Symptomatic pulmonary embolism during CDT re-
quired objective radiologic documentation by contrast
computed tomography angiography, ventilation/perfu-
sion scanning, or pulmonary angiography.
Statistical analysis. Continuous variables are reported
as means standard deviations. Comparison of continuous
variables was performed using the Student t test, and pro-
portions were compared using a z test for proportions.
Small proportions (numerator value 5) were compared
using the Fisher exact test. A 2 test of association was used
to compare subcategoric variables among frequency data.
Statistical significance was considered with a two-tailed or
one-tailed P .05. Statistical analysis was performed using
Stata 9.1 software (StataCorp, College Station, Tex).
RESULTS
Catheter-directed thrombolysis treatment was per-
formed on 202 limbs in 193 consecutive patients with acute
symptomatic iliofemoral or brachiosubclavian DVT be-
tween May 1995 and January 2007 at The Johns Hopkins
Medical Institutions. All DVT were initially suspected due
to acute swelling of the affected extremities associated with
pain. Clinical diagnosis was confirmed by duplex Doppler
ultrasound or computed tomography (CT) venography.
We performed CDT in 75 limbs of 61 cancer patients
(29men, 32 women) with a mean age of 55.8 14.5 years.
During the same time period, we performed CDT in 127
limbs of 117 noncancer patients (50 men, 67 women) with
a mean age of 39.5  15.5 years. Patients without cancer
were younger and had a higher prevalence of thrombo-
philia and anatomic risk factors for thromboembolism than
the patients with cancer (Table I).
The mean lytic treatment duration among cancer pa-
tients was 29.7  21.2 hours, similar to the 28.8  22.2
hours for patients without cancer (P  .7774). Adjunctive
PMT was used in 44 cancer patient limbs (58.7% of limbs
treated) and 68 limbs in noncancer patients (53.5% of limbs
treated; P .4789). The two groups did not differ in mean
total lytic dose or number of intraprocedural venograms
(lysis check) required (Table II).
Grade III or complete clot lysis was achieved in 50 of
75 limbs (66.7%) of cancer patients and in 82 of 127 limbs
(64.6%) of patients without cancer. Grade II or partial lysis
was achieved in 20 of 75 limbs (26.7%) of cancer patients
and 34 of 127 limbs (26.8%) of noncancer patients. Only a
small fraction of extremity DVT (5 of 75, 6.7%) among
cancer patients or noncancer patients (11 of 127, 8.7%) had
grade I lysis or persistent thrombosis. There were no sig-
nificant differences in the degree of clot lysis between the
two groups. Stenting was required after thrombolysis in
36.0% of cancer patients and in 21.3% of noncancer patients
(P  .0222).
Symptomatic pulmonary embolism during CDT treat-
ment was rare. One cancer patient (1.6%) and two noncan-
cer patients (1.7%) sustained a symptomatic pulmonaryembolism during percutaneous treatment (P  .9999).
Major bleeding occurred in three cancer patients (4.9%)
and four noncancer patients (3.4%; P  .6924). Minor
bleeding also occurred with a similar frequency in oncology
patients (6.6%) and nononcology patients (5.1%; P 
.7376). No intracranial hemorrhage occurred in either
patient group (Tables III). There were no significant dif-
ferences in major bleeding rates between different throm-
bolytic agents (Table IV).
Subgroup analyses found no significant differences in
clot lysis rates or complications between the patients with
and without cancer after being divided into brachiosubcla-
vian and iliofemoral DVT (Table V). Patients aged 70
showed a trend toward less complete clot lysis and greater
major bleeding. Otherwise age, sex, a history of DVT,
immobilization at the time of thrombosis, or type of cancer
had no impact on the efficacy or safety of CDT (Tables VI
and VII).
DISCUSSION
We report on the safety of 202 consecutive CDT treat-
ments of acute extremity DVT in 178 patients with and
without cancer. Despite their older age and the additional
comorbidities associated with an active malignancy, cancer
patients undergoing CDT for DVT experienced clinical
results that were comparable with noncancer patients. Both
patient groups had similar DVT lysis grade, pulmonary
embolism, and bleeding during CDT. These data from this
large comparative study of patients with and without cancer
indicate that CDT is a safe and effective treatment for
Table I. Baseline demographic and clinical characteristics
of the study population
Characteristic
Patients
with cancer,
61 (75 limbs)
Patients
without cancer,
117 (127 limbs) P
Age, mean  SD
years
55.8  14.5 39.5  15.5 .0001*
Gender, % (No.)
Male 47.5 (29/61) 42.7 (50/117) .5399
Female 52.5 (32/61) 57.3 (67/117) .5399
Clot locations, %
(No.)
Brachiosubclavian 28.0 (21/75) 23.6 (30/127) .4889
Iliofemoral 72.0 (54/75) 76.4 (97/127) .4889
Other risk factors, %
(No.)
Thrombophilia† 14.7 (11/75) 36.2 (46/127) .0010*
Previous DVT 46.7 (35/75) 52.0 (66/127) .4666
Immobilization‡ 21.3 (16/75) 28.4 (36/127) .2709
Anatomic risk
factor§
6.7 (5/75) 27.6 (35/127) .0003*
*Statistically significant.
†Documented biochemical hypercoagulable disorder.
‡Immobilization for 4 days 4 weeks before onset of deep venous
thrombosis.
§For example, May-Thurner syndrome in lower extremities or thoracic
outlet syndrome, effort induced thrombosis in upper extremities.cancer patients with acute symptomatic extremity DVT
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lected cancer patients as candidates for percutaneous
catheter-directed therapies for DVT.
Anticoagulation therapy for VTE in cancer patients has
been associated with a twofold to sixfold increased risk of
bleeding compared with patients without cancer.14,15 The
heightened risk for bleeding among cancer patients may be
one reason why application of CDT to acute extremity
DVT in cancer patients thus far has been restricted to
individual case reports or small case series,21-28 and some
studies of thrombolysis in the treatment of DVT have
specifically excluded cancer patients.16-18 We also have
noted reluctance of physicians at our institution to consider
CDT of DVT in cancer patients, perhaps reflecting these
Table II. Clinical outcomes of catheter-directed thrombo
Outcome
Patients
n  61
Treatment duration, mean  SD h 29.7  21
Urokinase doses, mean  SD million U 3.6  3.0
Reteplase doses, mean  SD U 23  0 (
Alteplase doses, mean  SD mg 15.1  10
Intra-procedure venograms (lysis checks),
mean  SD No. 2.5  0.9
Clot reduction, % (No.)
Grade III 66.7
Grade II 26.7
Grade I 6.7
Stent placements, (No.) 36.0
Complications during CDT, % (No.)
Major bleeding 4.9
Minor bleeding 6.6
Pulmonary embolism 1.6
CDT, Catheter-directed thrombolysis; TPA, tissue plasminogen activator.
aStatistically significant.
Table III. Bleeding complications associated with
catheter-directed thrombolysis in patients with and
without cancer
Bleeding complications
Patients
with cancer,
n  61
Patients
without cancer,
n  117
Major bleeding, % (No.)
GI bleed 1.6 (1) 0
Intra-abdominal wall 1.6 (1) 0
Access site hematoma 0 2.6 (3)
Around a central line 0 0.9 (1)
Acute anemia with no
identified bleed 1.6 (1) 0
Total 4.9 (3) 3.4 (4)
Minor bleeding, % (No.)
Hematuria 1.6 (1) 0.9 (1)
Access site hematoma 3.3 (2) 1.7 (2)
Venous extravasation 1.6 (1) 0
Hemoptysis 0 0.9 (1)
Intra-abdominal wall 0 0.9 (1)
Retroperitoneal 0 0.9 (1)
Total 6.6 (4) 5.1 (6)concerns noted in the literature. However, previous clinicalexperience using alteplase or urokinase in the treatment of
pulmonary embolism suggested that systemic thrombolysis
was safe and effective for patients with and without cancer,
although the reperfusion rate among cancer patients was
less at 24 hours.29 This experience prompted us to review
our institutional experience with CDT in the treatment of
acute symptomatic extremity DVT in patients with and
without cancer.
Comparable with the previously published experience
in thrombolysis for pulmonary embolism,29 we noted sim-
ilar safety of CDT in cancer patients and patients without
cancer. Our results also compare favorably with those ob-
tained in a national multicenter registry.11 Adjuvant use of
PMT has been associated with decreased treatment dura-
tion30 and may have contributed to the excellent results
obtained in this study. During CDT, only 4.9% of cancer
patients and 3.4% of noncancer patients had a major hem-
orrhage and no intracranial hemorrhages occurred, which
are promising results when compared with the 11% inci-
dence of major hemorrhage noted in a multicenter CDT
DVT registry.11 Our results demonstrate that percutaneous
catheter-directed therapy for a limited duration is as safe in
cancer patients as in noncancer patients.
Several limitations of our study deserve discussion. The
Table IV. Comparison of treatment complications
associated with different thrombolytic agents during
catheter-directed thrombolysis
Complications during CDT
Urokinase
(n  60)
Alteplase
(n  109)
Reteplase
(n  9)
Major bleeding, % (No.) 5.0 (3) 3.7 (4) 0 (0)
Minor bleeding, % (No.) 3.3 (2) 6.4 (7) 11.1 (1)
Pulmonary embolism, % (No.) 1.7 (1) 1.8 (2) 0 (0)
CDT, Catheter-directed thrombolysis.
in patients with and without cancer
ancer,
mbs)
Patients without cancer,
n  117 (127 limbs) P
28.8  22.2 .7774
limbs) 4.8  5.1 (41 limbs) .2157
b) 22.5  9.9 (8 limbs) .9999
limbs) 17.5  12.5 (78 limbs) .2672
2.4  1.0 .4839
5) 64.6 (82/127) .7619
5) 26.8 (34/127) .9872
) 8.7 (11/127) .6122
5) 21.3 (27/127) .0222a
) 3.4 (4/117) .6924
) 5.1 (6/117) .7376
) 1.7 (2/117) .9999lysis
with c
(75 li
.2
(27
1 lim
.1 (47
(50/7
(20/7
(5/75
(27/7
(3/61
(4/61
(1/61present study is a retrospective consecutive case series;
(1/3
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Although an unequal distribution of risk factors for recur-
rent VTE and bleeding may have influenced study results,
we believe that the clinical characteristics of the two
patient groups tend to favor an inferior outcome for the
cancer patients. Cancer patients have been reported to
have a threefold higher risk of recurrent VTE and two-
fold higher risk of major bleeding compared with pa-
tients without cancer.14,15 As a consequence, the excel-
lent outcomes obtained for both patient groups in our
Table V. Clinical outcomes of catheter-directed thrombo
thrombosis
Outcome
Brachiosubclavia
Patients
with cancer
Pa
witho
Total patients (limbs) 20 (21) 30
Clot lysis, % (No.)
Grade III 61.9 (13/21) 66.7
Grade II 23.8 (5/21) 16.7
Grade I 14.3 (3/21) 16.7
Complications during CDT % (No.)
Major bleeding 0 (0/20) 3.3
Minor bleeding 5.0 (1/20) 6.7
Pulmonary embolism 0 (0/20) 3.3
Table VI. Catheter-directed thrombolysis clot lysis in pat
Factors Limbs, No. Grade I
Sex
Male 40 67
Female 35 65
Age
50 24 79
50-70 39 64
70 12 50
Previous DVT
Yes 35 65
No 40 67
Immobilization
Yes 16 50
No 59 71
Cancer
Leukemia 7 57
Lymphoma 4 50
Genitourinary 2 100
Breast 3 66
Gynecologic 16 62
Lung 11 81
CNS 3 33
Unknown primary 2 100
Pancreatic 2 100
Bone 1
Colon 6 83
Prostate 8 50
Skin 3 33
Testicular 2 100
Other 5 80
CNS, Central nervous system; DVT, deep vein thrombosis.study support our assertion that CDT should be seri-ously considered for appropriate candidates regardless of
the presence of cancer.
Another potential weakness of our study design is the use
of three different thrombolytic agents during the study.
Therefore, we cannot exclude the possibility that the study
outcome was influenced by thrombolytic choice by individual
providers. Although this variable could have influenced our
results, no differences were evident in the use of the different
thrombolytic agents between the two groups and there are no
existing data from randomized controlled trials that indicate
of brachiosubclavian and iliofemoral deep venous
ombosis Iliofemoral Thrombosis
s
ncer P
Patients
with cancer
Patients
without cancer P
41 (54) 87 (97)
30) .7263 68.5 (37/54) 63.9 (62/97) .5687
0) .7218 27.8 (15/54) 29.9 (29/97) .7833
0) .9999 3.7 (2/54) 6.2 (6/97) .7120
0) .9999 7.3 (3/41) 3.4 (3/87) .3841
0) .9999 7.3 (3/41) 4.6 (4/87) .6795
0) .9999 2.4 (1/41) 1.1 (1/87) .9999
with cancer
(No.) Grade II, % (No.) Grade I, % (No.)
7) 30.0 (12) 2.5 (1)
3) 22.9 (8) 11.4 (4)
9) 12.5 (3) 8.3 (2)
5) 30.8 (12) 5.1 (2)
) 41.7 (5) 8.3 (1)
3) 28.6 (10) 5.7 (2)
7) 25.0 (10) 7.5 (3)
) 43.8 (7) 6.3 (1)
2) 22.0 (13) 6.8 (4)
) 28.6 (2) 14.3 (1)
) 50.0 (2) 0
) 0 0
) 0 33.3 (1)
0) 37.5 (6) 0
) 9.1 (1) 9.1 (1)
) 66.7 (2) 0
) 0 0
) 0 0
0 100.0 (1)
) 16.7 (1) 0
) 50.0 (4) 0
) 66.7 (2) 0
) 0 0
) 0 20.0 (1)lysis
n thr
tient
ut ca
(30)
(20/
(5/3
(5/3
(1/3
(2/3ients
II, %
.5 (2
.7 (2
.2 (1
.1 (2
.0 (6
.7 (2
.5 (2
.0 (8
.2 (4
.1 (4
.0 (2
.0 (2
.7 (2
.5 (1
.8 (9
.3 (1
.0 (2
.0 (2
0
.3 (5
.0 (4
.3 (1
.0 (2
.0 (4the superiority of one thrombolytic agent for CDT.
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included patients with upper and lower extremity proximal
DVT treated with CDT in our analysis. Although the
etiology of thromboses in these two locations may differ,
we believe that valid conclusions about the safety of CDT
can be drawn by examining both these populations of
patients.
Finally, as a retrospective study, our results could be
influenced by patient selection bias. As a consequence,
these results may not be generalizable to all patients with
acute extremity DVT. Nevertheless, we used standardized
patient selection criteria and enrolled consecutive patients;
therefore, use of these criteria should allow other investiga-
tors to identify patients who could potentially derive similar
clinical benefits. Prospective studies would be useful to
confirm these findings.
CONCLUSION
Our results indicate that catheter-directed thrombol-
ysis is as safe in cancer patients as it is in noncancer
patients for the treatment of acute proximal deep venous
thrombosis. Therefore, appropriately selected cancer pa-
tients should not be excluded from receiving catheter-
directed therapies for acute deep venous thrombosis.
Prospective, randomized studies are needed to confirm
Table VII. Bleeding complications associated with
catheter-directed thrombolysis in cancer patients
Factors
Patients,
No.
Major bleeding,
% (No.)
Minor bleeding,
% (No.)
Sex
Male 29 6.9 (2) 6.9 (2)
Female 32 3.1 (1) 6.3 (2)
Age, years
50 19 0 (0) 0 (0)
50-70 32 3.1 (1) 12.5 (4)
70 10 20.0 (2) 0 (0)
Previous DVT
Yes 26 3.8 (1) 7.7 (2)
No 35 5.7 (2) 5.7 (2)
Immobilization
Yes 11 9.1 (1) 0
No 50 4.0 (2) 8.0 (4)
Cancer
Leukemia 6 0 0
Lymphoma 4 0 0
Genitourinary 2 0 0
Breast 3 0 0
Gynecologic 14 7.1 (1) 7.1 (1)
Lung 8 0 12.5 (1)
CNS 2 0 0
Unknown primary 2 0 0
Pancreatic 2 0 0
Bone 1 0 0
Colon 5 20 (1) 0
Prostate 5 20 (1) 20 (1)
Skin 2 0 0
Testicular 1 0 0
Other 4 0 25.0 (1)
CNS, Central nervous system; DVT, deep vein thrombosis.these promising results.AUTHOR CONTRIBUTIONS
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